Trials / Completed
CompletedNCT04798586
MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma
A PHASE I, OPEN LABEL STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETIC OF PF 06863135, A B CELL MATURATION ANTIGEN (BCMA) CD3 BISPECIFIC ANTIBODY, AS A SINGLE AGENT IN JAPANESE PARTICIPANTS WITH RELAPSED/REFRACTORY ADVANCED MULTIPLE MYELOMA
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to confirm the safety and tolerability of elranatamab (PF-06863135) in Japanese participants with relapsed or refractory MM.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Elranatamab (PF-06863135) | BCMA-CD3 bispecific antibody |
Timeline
- Start date
- 2021-03-22
- Primary completion
- 2022-05-27
- Completion
- 2023-05-17
- First posted
- 2021-03-15
- Last updated
- 2024-09-27
- Results posted
- 2024-09-27
Locations
2 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04798586. Inclusion in this directory is not an endorsement.